Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London this week, and will be presenting a company update as part of the Biotech Investment Programme at 2pm on May 31st. This will be the 14th annual meeting of this partnering conference.
Dr Ribeiro said: “This is the first time that we’ll have participated in this event, so I’m very much looking forward to engaging with the attendees from the investor and biotech communities. Our point-of-care test for monitoring active neutrophil elastase in diseases such as COPD and cystic fibrosis is in its final stages of development, so this is an excellent time for us to be meeting prospective partners for this exciting technology.”
Any requests from either pharmaceutical companies or academic researchers for support to measure active proteases or other inflammatory biomarkers can be directed to info@proaxsis.com.
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
Related News
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, has formed a new partnership with Ulster University, the largest university …
ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference …
Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for …
